NICE: how to switch NHS patients from Remicade to a biosimilar
This article was originally published in Scrip
The National Institute for Health and Care Excellence (NICE) has produced some "practical advice" for NHS staff on how to manage the introduction of the two biosimilar versions of Merck & Co/J&J's Remicade (infliximab) that were launched in the UK in February this year following further patent expiries on the originator.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.